Horizon Pharma PLC (NASDAQ: HZNP) released its most recent quarterly earnings report before the markets opened on Monday. The firm said that it had $0.41 in earnings per share (EPS) and $289.5 million in revenue, compared with consensus estimates that called for $0.10 in EPS and revenue of $237 million. The same period of last year reportedly had EPS of $0.56 and $257.38 million in revenue.
During the second quarter, net sales of Horizon Pharma’s medicines for rare diseases increased 70% compared to last year. Also, net sales for rare disease medicines represented 55% of total net sales, up from 36% from the second quarter of 2016.
At the same time, Horizon Pharma completed its acquisition of River Vision and its biologic, teprotumumab. Teprotumumab is in late-stage development to treat thyroid eye disease, a rare, debilitating and painful condition with no current FDA-approved therapy.
In terms of the outlook for the full year, the company increased its guidance of net sales to the range of $1.01 billion to $1.02 billion and EBITDA to $340 million to $315 million. The previous ranges were net sales of $985 million to $1.02 billion and $315 million to $350 million in EBITDA.
The consensus estimates are $0.82 in EPS and $991.23 million in revenue for the full year.
Cash and cash equivalents totaled $561.5 million at the end of the quarter, compared with $516.1 million at the end of the previous fiscal year.
Timothy P. Walbert, board chair, president and chief executive, commented:
Our rare disease medicines generated another quarter of strong performance, increasing 70 percent versus a year ago. As a result of strong second-quarter performance across our business units, we are raising our full-year sales and adjusted EBITDA guidance.
Shares of Horizon Pharma were last seen up over 6% at $13.47, with a consensus analyst price target of $15.73 and a 52-week range of $9.45 to $23.44.
Essential Tips for Investing (Sponsored)
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
